Maher Hanoun

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Journal: Haematologica
Published: April 20, 2026

Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous LRBA mutation.

Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous LRBA mutation.

Journal: Haematologica
Published: January 10, 2026

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Journal: The Lancet. Haematology
Published: September 01, 2025

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy.

Journal: American journal of hematology
Published: August 18, 2025

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Journal: Leukemia
Published: August 15, 2025

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma.

Journal: Blood
Published: August 04, 2025

IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.

Journal: Blood
Published: August 04, 2025

VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.

VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.

Journal: Annals of hematology
Published: April 20, 2025

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.

Journal: Leukemia
Published: April 03, 2025

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients.

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia - long-term follow-up with focus on younger patients.

Journal: Blood cancer journal
Published: January 07, 2025

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.

Journal: Cancer cell
Published: November 22, 2024

Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML.

Age-stratified machine learning identifies divergent prognostic significance of molecular alterations in AML.

Journal: HemaSphere
Published: October 23, 2024
Showing 1-12 of 54

Last Updated: 09/26/2026